Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.36 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7054224 | 0.87 | CPA3 (0.55) | CPA3ACENAALAD2SRRFOLH1 | |
| SCHEMBL7049052 | 0.77 | FOLH1 (0.35) | FFAR1USP2TSHRCYP19A1FOLH1 | |
| SCHEMBL7047144 | 0.76 | LMNA (0.34) | USP2TSHRALDH1A1FOLH1BCHE | |
| SCHEMBL7050280 | 0.75 | CPA3 (0.44) | CPA3FFAR1ALDH1A1CYP3A4NAALAD2 | |
| SCHEMBL28617085 | 0.75 | BCHE (0.38) | CPA3FFAR1USP2TSHRALDH1A1 | |
| SCHEMBL7609056 | 0.73 | CPA3 (0.53) | CPA3FFAR1ACENAALAD2FOLH1 | |
| SCHEMBL7052221 | 0.72 | FOLH1 (0.35) | CPA3FFAR1USP2TSHRALDH1A1 | |
| SCHEMBL7049737 | 0.72 | KIF11 (0.33) | CPA3FFAR1USP2TSHRALDH1A1 | |
| SCHEMBL7048114 | 0.72 | FOLH1 (0.47) | FOLH1 | |
| SCHEMBL1373610 | 0.71 | FOLH1 (0.40) | USP2TSHRALDH1A1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| US-6265609-B1 | INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY; IN DRUGS TO TREAT GLUTAMATE ABNORMALITIES; COMPULSIVE DISORDERS AND PROSTATE DISEASES, TO EFFECT NEURONAL ACTIVITIES | GUILFORD PHARMACEUTICALS INC. | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | CPA3 193/4885FFAR1 3784/4885USP2 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.